Get the Stockscreener App
14.40
0.14%
0.02
Pre-market:
14.41
0.010
+0.07%
Schrodinger Inc stock is traded at $14.40, with a volume of 865.74K.
It is up +0.14% in the last 24 hours and up +9.67% over the past month.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.
See More
Previous Close:
$14.38
Open:
$14.515
24h Volume:
865.74K
Relative Volume:
0.64
Market Cap:
$1.08B
Revenue:
$255.87M
Net Income/Loss:
$-103.27M
P/E Ratio:
-10.21
EPS:
-1.4109
Net Cash Flow:
$12.46M
1W Performance:
-8.86%
1M Performance:
+9.67%
6M Performance:
-18.92%
1Y Performance:
-41.51%
1-Day Range:
$14.28
$14.73
1-Week Range:
$14.23
$16.47
52-Week Range:
$10.95
$27.63
Schrodinger Inc Stock (SDGR) Company Profile
Name
Schrodinger Inc
Sector
Industry
Phone
503-299-1150
Address
1540 BROADWAY, NEW YORK, NY
Compare SDGR vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SDGR
Schrodinger Inc
|
14.40 | 1.07B | 255.87M | -103.27M | 12.46M | -1.4109 |
VEEV
Veeva Systems Inc
|
167.24 | 28.17B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
59.22 | 11.32B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
48.59 | 8.34B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
87.84 | 7.41B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
62.86 | 4.92B | 646.34M | -512.40M | 202.76M | -6.6871 |
Schrodinger Inc Stock (SDGR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Neutral |
| Aug-15-25 | Downgrade | Citigroup | Buy → Neutral |
| Aug-14-25 | Initiated | Barclays | Overweight |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-02-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| May-05-23 | Resumed | Piper Sandler | Overweight |
| Dec-19-22 | Initiated | Goldman | Neutral |
| Mar-01-22 | Initiated | Citigroup | Buy |
| Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-11-21 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-13-21 | Initiated | Berenberg | Buy |
| Sep-01-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-25-21 | Initiated | Craig Hallum | Buy |
| Nov-23-20 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-02-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-02-20 | Initiated | Jefferies | Hold |
| Mar-02-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Schrodinger Inc Stock (SDGR) Latest News
Schrodinger finalizes separation agreement with former chief commercial officer - Investing.com
Schrodinger separation of Mannix Aklian as Chief Commercial Officer confirmed - TradingView
Severance package for ex-commercial chief at Schrödinger (NASDAQ: SDGR) - Stock Titan
(SDGR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Schrödinger’s Call Review: The Power of a Final Call - DualShockers
10 Top Tech Companies in Munich - Built In
Recursion vs. Schrodinger: Comparing Biotech and Software Drug Discovery Strategies in 2026News and Statistics - IndexBox
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Does Schrödinger (SDGR) Changing Its CCO While Reaffirming Guidance Recast Its Commercial Playbook? - Sahm
Schrodinger Inc stock (US80655G1067): shares extend late-May rebound on Nasdaq - AD HOC NEWS
Schrödinger, Inc. Hits Day High with Strong 7.34% Intraday Surge - MarketsMojo
Schrödinger, Inc. Hits Day High with Strong Intraday Performance, Up 7.39% - Markets Mojo
Companies Like Schrödinger (NASDAQ:SDGR) Are In A Position To Invest In Growth - Moomoo
Another Indie Matched Mina The Hollower's Review Scores This Week And No One Noticed - TheGamer
A Look at Schrodinger Inc (SDGR) After 6.9% Gain -- GF Value $26 - GuruFocus
SDGR Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Schrodinger Inc stock (US80655G1067): shares steady after May gains on Nasdaq - AD HOC NEWS
Schrödinger slides after early-stage trial data for cancer therapy - MSN
(SDGR) Risk Channels and Responsive Allocation - Stock Traders Daily
How The Schrödinger (SDGR) Investment Story Is Shifting As Analysts Reset Price Targets - Yahoo Finance
Stephens Investment Management Group LLC's Schrodinger Inc(SDGR) Holding History - GuruFocus
Schrodinger (SDGR) Issues Stock Options and RSUs to New Employees - GuruFocus
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - pharmiweb.com
Schrodinger reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Schrödinger Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Schrodinger Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Schrödinger Announces Leadership Change Amid Maintained 2026 Outlook - TipRanks
Schrödinger, Inc. Reaffirms Earnings Guidance for the Second Quarter Ending June 30, 2026 and Fiscal Year Ending December 31, 2026 - marketscreener.com
Leadership change at Schrödinger (NASDAQ: SDGR) as CCO departs and outlook held - Stock Titan
My Top 3 Biotech Stocks for May 2026 - Yahoo Finance
Schrödinger Balances Growth and Losses in Earnings Call - TipRanks
Schrödinger, Inc. Announces Executive Changes - marketscreener.com
SDGR: Improved funding and tech adoption are accelerating drug discovery and portfolio growth - TradingView
Schrodinger Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Schrodinger : SDGR - 24/7 Wall St.
Cheminformatics Market Size, Share | Growth Forecast [2034] - Fortune Business Insights
Schrodinger stock (US80655G1067): AI-powered drug discovery story after latest earnings - AD HOC NEWS
Rubric Capital and David Rosen disclose 9.28% position in Schrodinger (SDGR) - Stock Titan
(SDGR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
SDGR Maintained by Morgan Stanley -- Price Target Lowered to $17 - GuruFocus
Morgan Stanley Maintains Schrodinger(SDGR.US) With Hold Rating, Cuts Target Price to $17 - Moomoo
Morgan Stanley Lowers Price Target on Schrodinger to $17 From $19, Keeps Equalweight Rating - marketscreener.com
Schrodinger, Inc. Stock 12‑Month Price Target Cut to $20.88, Implies 64% Upside - TradingView
SDGR: Hosted revenue jumps to 34% as broad-based growth and new products drive positive momentum - TradingView
SDGR Stock Price, Quote & Chart | SCHRODINGER INC (NASDAQ:SDGR) - ChartMill
Evogene to Present at the 24th Schrödinger European User Group Meeting - PR Newswire
TradingKey - TradingKey
UBS Group AG Buys 489,059 Shares of Schrodinger, Inc. $SDGR - MarketBeat
Number of shareholders of Schrodinger, Inc. – LS:A2PY7M - TradingView
Schrodinger Inc stock (US80655G1067): Q1 loss and revenue miss weigh on shares - AD HOC NEWS
Schrodinger Inc Stock (SDGR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.25%
1.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):